- Home
- SDA vs IMMP Comparison
SDA vs IMMP Comparison
Compare SDA & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDA
- IMMP
- Stock Information
- Founded
- SDA 2007
- IMMP 1987
- Country
- SDA China
- IMMP Australia
- Employees
- SDA N/A
- IMMP N/A
- Industry
- SDA Blank Checks
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- SDA Finance
- IMMP Health Care
- Exchange
- SDA Nasdaq
- IMMP Nasdaq
- Market Cap
- SDA 213.5M
- IMMP 256.1M
- IPO Year
- SDA N/A
- IMMP N/A
- Fundamental
- Price
- SDA $1.86
- IMMP $1.88
- Analyst Decision
- SDA Strong Buy
- IMMP Buy
- Analyst Count
- SDA 2
- IMMP 1
- Target Price
- SDA $4.75
- IMMP $7.00
- AVG Volume (30 Days)
- SDA 507.5K
- IMMP 142.4K
- Earning Date
- SDA 10-27-2025
- IMMP 02-22-2026
- Dividend Yield
- SDA N/A
- IMMP N/A
- EPS Growth
- SDA N/A
- IMMP N/A
- EPS
- SDA N/A
- IMMP N/A
- Revenue
- SDA $461,120,000.00
- IMMP $3,306,742.00
- Revenue This Year
- SDA $16.19
- IMMP N/A
- Revenue Next Year
- SDA $16.53
- IMMP N/A
- P/E Ratio
- SDA N/A
- IMMP N/A
- Revenue Growth
- SDA 13.17
- IMMP 31.28
- 52 Week Low
- SDA $1.54
- IMMP $1.32
- 52 Week High
- SDA $10.73
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- SDA 37.22
- IMMP 51.34
- Support Level
- SDA $1.85
- IMMP $1.78
- Resistance Level
- SDA $2.03
- IMMP $2.08
- Average True Range (ATR)
- SDA 0.21
- IMMP 0.08
- MACD
- SDA 0.01
- IMMP -0.01
- Stochastic Oscillator
- SDA 25.00
- IMMP 51.16
About SDA SunCar Technology Group Inc.
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.
About IMMP Immutep Limited
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.